What’s the Buzz on Drug Development in 2012? MM&M's “Pipeline 2012” Features GfK Commentary

Medical Marketing & Media
December 2011

Medical Marketing & Media's annual "Pipeline" was just released! This guide to late-stage R&D front-runners and tip sheet on what’s generating the most buzz in drug development for 2012 profiles a dozen agents on deck, plus 203 products in the wings, in major categories such as cardiovascular, infectious disease, neurology, oncology, rheumatology and metabolic. Seven GfK HealthCare marketing researchers are featured providing their expert opinions on both the therapeutic classes and specific drugs covered.

To download Medical Marketing & Media’s Pipeline 2012, click here.



For more insights on these therapeutic areas from the experts included in the article, please contact the GfK HealthCare consultants listed below:

Cardiovascular
Portia Gordon, Vice President

Infectious Disease
Will Leskin, Senior Vice President

Neurology
Louise Gillis, Associate Vice President
Marite Talbergs, Senior Vice President

Oncology
Petra Maertens, Director

Rheumatology
Geoff Penney, Vice President

Metabolic
Dave Jacobson, Senior Vice President, Roper Global Diabetes Group

Orphan Disease
Marite Talbergs, Senior Vice President